Perception of PrEP-related stigma in PrEP users: Results from the ANRS-PREVENIR cohort.


Journal

HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392

Informations de publication

Date de publication:
08 2023
Historique:
received: 07 11 2022
accepted: 20 03 2023
medline: 8 8 2023
pubmed: 13 4 2023
entrez: 12 4 2023
Statut: ppublish

Résumé

Since the advent of HIV pre-exposure prophylaxis (PrEP), stigma has been shown to be a major barrier to its uptake and adherence. It is therefore essential to define the proportion of users who consider that PrEP can negatively impact their image and the factors associated with this perception. We performed a multivariable logistic regression on data from the 2567 participants in the ANRS-PREVENIR study who answered the outcome question. Almost one-third of the sample (comprising mostly cisgender men who have sex with men [94.3%]) considered that taking PrEP could give others a negative image of them. Younger participants (adjusted odds ratio [aOR] 0.98; 95% confidence interval [CI] 0.97-0.99) and more psychologically vulnerable participants (i.e., lower self-esteem score [aOR 0.98; 95% CI 0.96-0.99] and higher depression score [aOR 1.02; 95% CI 1.00-1.03]) were also more likely to have this perception. In contrast, participants encouraged to take PrEP by their main partner (aOR 0.67; 95% CI 0.51-0.88) and friends (aOR 0.79; 95% CI 0.66-0.95), and those who protected themselves more because they had knowledge of their most recent sexual partner's HIV status (aOR 0.83; 95% CI 0.69-0.99) and systematic use of PrEP and/or condoms during intercourse in the previous 3 months (aOR 0.80; 95% CI 0.67-0.96) were less likely to have this perception. Given the strong interrelation between stigmatization (real or perceived), risky behaviours and adherence, our results emphasize the need for HIV prevention campaigns to promote a positive image of PrEP users. They also show that stigmatization and its effects need to be fully considered to improve HIV prevention offers to current and potential PrEP users who are most likely to be psychologically vulnerable.

Identifiants

pubmed: 37046178
doi: 10.1111/hiv.13491
doi:

Banques de données

ClinicalTrials.gov
['NCT03113123']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

938-945

Informations de copyright

© 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.

Références

Molina J-M, Capitant C, Spire B, et al. On-demand Preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-2246.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet Lond Engl. 2016;387:53-60.
Molina J-M, Ghosn J, Assoumou L, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV. 2022;9:e554-e562.
Rosengren AL, Lelutiu-Weinberger C, Woodhouse EW, Sandanapitchai P, Hightow-Weidman LB. A scoping review of HIV pre-exposure prophylaxis stigma and implications for stigma-reduction interventions for men and transwomen who have sex with men. AIDS Behav [Internet]. 2021;25:2054-2070 [cited 2021 Apr 20]; Available from. doi:10.1007/s10461-020-03135-2
Haire BG. Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence - a narrative review. HIVAIDS Auckl NZ. 2015;7:241-249.
Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review. Adv Ther. 2020;37:1778-1811.
Haldar P, Reza-Paul S, Daniel RA, et al. A rapid review of pre-exposure prophylaxis for HIV in the Asia-Pacific region: recommendations for scale up and future directions. Sex Health. 2021;18:31-40.
Pleuhs B, Quinn KG, Walsh JL, Petroll AE, John SA. Health care provider barriers to HIV pre-exposure prophylaxis in the United States: a systematic review. AIDS Patient Care STDS. 2020;34:111-123.
Grace D, Jollimore J, MacPherson P, Strang MJP, Tan DHS. The pre-exposure prophylaxis-stigma paradox: learning from Canada's first wave of PrEP users. AIDS Patient Care STDS. 2018;32:24-30.
Puppo C, Spire B, Morel S, et al. How PrEP users constitute a community in the MSM population through their specific experience and management of stigmatization. The example of the French ANRS-PREVENIR study. AIDS Care. Taylor & Francis. 2020;32:32-39.
Brooks RA, Nieto O, Landrian A, Fehrenbacher A, Cabral A. Experiences of pre-exposure prophylaxis (PrEP)-related stigma among black MSM PrEP users in Los Angeles. J Urban Health Bull N Y Acad Med. 2020;97:679-691.
Edeza A, Karina Santamaria E, Valente PK, Gomez A, Ogunbajo A, Biello K. Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies. AIDS Care. 2021;33:697-705.
Dubov A, Galbo P, Altice FL, Fraenkel L. Stigma and shame experiences by MSM who take PrEP for HIV prevention: a qualitative study. Am J Mens Health. 2018;12:1843-1854.
Calabrese SK. Understanding, contextualizing, and addressing PrEP stigma to enhance PrEP implementation. Curr HIV/AIDS Rep. 2020;17:579-588.
Babel RA, Wang P, Alessi EJ, Raymond HF, Wei C. Stigma, HIV risk, and access to HIV prevention and treatment services among men who have sex with men (MSM) in the United States: a scoping review. AIDS Behav. 2021;1-31:3574-3604.
Berg RC, Ross MW, Weatherburn P, Schmidt AJ. Structural and environmental factors are associated with internalised homonegativity in men who have sex with men: findings from the European MSM internet survey (EMIS) in 38 countries. Soc Sci Med. 2013;78:61-69.
Orth U, Robins RW. Understanding the link between low self-esteem and depression. Curr Dir Psychol Sci. 2013;22:455-460.
Molina J-M, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4:e402-e410.
Mehrotra ML, Glidden DV, McMahan V, et al. The effect of depressive symptoms on adherence to daily oral PrEP in men who have sex with men and transgender women: a marginal structural model analysis of the iPrEx OLE study. AIDS Behav. 2016;20:1527-1534.
Mabire X, Puppo C, Morel S, et al. Pleasure and PrEP: pleasure-seeking plays a role in prevention choices and could Lead to PrEP initiation. Am J Mens Health. 2019;13(1). doi:10.1177/1557988319827396

Auteurs

C Protiere (C)

Aix Marseille Univ, INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

L Sagaon-Teyssier (L)

Aix Marseille Univ, INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

C Donadille (C)

Aix Marseille Univ, INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

A Sow (A)

Aix Marseille Univ, INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

G Gaubert (G)

Aix Marseille Univ, INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

G Girard (G)

Aix Marseille Univ, INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

M Mora (M)

Aix Marseille Univ, INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

L Assoumou (L)

Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, Paris, France.

L Beniguel (L)

Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, Paris, France.

D Michels (D)

AIDES, Paris, France.
Coalition PLUS, Community-based Research Laboratory, Paris, France.

J Ghosn (J)

University Paris Diderot, Sorbonne Paris Cité, Bichat Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.

D Costagliola (D)

Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, Paris, France.

D Rojas Castro (D)

Aix Marseille Univ, INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.
AIDES, Paris, France.
Coalition PLUS, Community-based Research Laboratory, Paris, France.

J-M Molina (JM)

Hospital Saint-Louis, Assistance Publique Hôpitaux de Paris, Department of Infectious diseases, Paris, France.

B Spire (B)

Aix Marseille Univ, INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH